Fast Market Research

Pancreatic Cancer - Pipeline Review, H2 2016 - New Market Study Published

Fast Market Research announces the availability of the new Global Markets Direct report, "Pancreatic Cancer - Pipeline Review, H2 2016", on their comprehensive research portal


Boston, MA -- (SBWIRE) -- 02/22/2017 -- Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pancreatic Cancer - Pipeline Review, H2 2016, provides an overview of the Pancreatic Cancer (Oncology) pipeline landscape.

Pancreatic cancer is a disease in which malignant (cancer) cells are found in the tissues of the pancreas. This is also called exocrine cancer. Signs and symptoms include upper abdominal pain that may radiate to back, yellowing of skin and the whites of eyes (jaundice), loss of appetite, weight loss, depression and blood clots. Predisposing factors include age, gender, smoking, diabetes and family history. Treatment includes surgery, chemotherapy and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Pancreatic Cancer - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Pancreatic Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

Get More Details on this Report and a Full Table of Contents at Pancreatic Cancer - Pipeline Review, H2 2016

The Pancreatic Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Pancreatic Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 1, 15, 106, 112, 1, 3, 249, 38 and 5 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 18, 7, 50 and 7 molecules, respectively.

Pancreatic Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Report Scope

-The pipeline guide provides a snapshot of the global therapeutic landscape of Pancreatic Cancer (Oncology).

-The pipeline guide reviews pipeline therapeutics for Pancreatic Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

-The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

-The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

-The pipeline guide reviews key companies involved in Pancreatic Cancer (Oncology) therapeutics and enlists all their major and minor projects.

-The pipeline guide evaluates Pancreatic Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

-The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

-The pipeline guide reviews latest news related to pipeline therapeutics for Pancreatic Cancer (Oncology)

Reasons to Get this Report

-Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

-Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

-Find and recognize significant and varied types of therapeutics under development for Pancreatic Cancer (Oncology).

-Classify potential new clients or partners in the target demographic.

-Develop tactical initiatives by understanding the focus areas of leading companies.

-Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

-Formulate corrective measures for pipeline projects by understanding Pancreatic Cancer (Oncology) pipeline depth and focus of Indication therapeutics.

Companies Mentioned in this Report: 3M Drug Delivery Systems, 4SC AG, AB Science SA, AbbVie Inc, AbGenomics International Inc, Ability Pharmaceuticals SL, Acetylon Pharmaceuticals Inc, Adamed Sp z oo, Adamis Pharmaceuticals Corp, Aduro BioTech Inc, Advantagene Inc, Advaxis Inc, Agenus Inc, AGV Discovery SAS, AIMM Therapeutics BV, Alchemia Ltd, Alissa Pharma, Allinky Biopharma, Almac Discovery Ltd, Altor BioScience Corp, Ambrx Inc, amcure GmbH, American Gene Technologies International Inc, Amgen Inc, Anavex Life Sciences Corp, Andarix Pharmaceuticals Inc, ANP Technologies Inc, AntiCancer Inc, APEIRON Biologics AG, Aphios Corp, APIM Therapeutics AS, Apogenix GmbH, Aposense Ltd, ARMO Biosciences Inc, ArQule Inc, Array BioPharma Inc, Astellas Pharma Inc, AstraZeneca Plc, ATLAB Pharma SAS, Aurigene Discovery Technologies Ltd, AVEO Pharmaceuticals Inc, Axcentua Pharmaceuticals AB, Azaya Therapeutics Inc, Basilea Pharmaceutica Ltd, Bavarian Nordic A/S, Bayer AG, BeiGene Ltd, Bellicum Pharmaceuticals Inc, Berg LLC, BerGenBio AS, Betta Pharmaceuticals Co Ltd, Bexion Pharmaceuticals LLC, BeyondSpring Pharmaceuticals Inc, Bio-Path Holdings Inc, BioLineRx Ltd, Biomar Microbial Technologies, Biomunex Pharmaceuticals, Bioncotech Therapeutics SL, Bionomics Ltd, BioNTech AG, BiOrion Technologies BV, Biotest AG, Biouniversa srl, BLR Bio LLC, Boehringer Ingelheim GmbH, Boston Biomedical Inc, Bristol-Myers Squibb Company, Cadila Pharmaceuticals Ltd, Calithera Biosciences Inc, Cantargia AB, Cascadian Therapeutics Inc, Cavion LLC, Celgene Corp, Cellceutix Corp, Cellular Biomedicine Group Inc, Celprogen Inc, Celyad SA, Centrose LLC, Ceronco Biosciences, ChemoCentryx Inc, Chiome Bioscience Inc, Chugai Pharmaceutical Co Ltd, Clovis Oncology Inc, COARE Biotechnology Inc, Concordia International Corp, Confluence Life Sciences Inc, Cornerstone Pharmaceuticals Inc, Critical Outcome Technologies Inc, CrystalGenomics Inc, CTI BioPharma Corp, Cyclacel Pharmaceuticals Inc, CytomX Therapeutics Inc, CytRx Corp, CyTuVax BV, Daewoong Pharmaceutical Co Ltd, Daiichi Sankyo Company Ltd, DEKK-TEC Inc, Diffusion Pharmaceuticals Inc, Eisai Co Ltd, Eleison Pharmaceuticals LLC, Eli Lilly and Company, Endor Nanotechnologies SL, Ensemble Therapeutics Corp, Ensol Biosciences Inc, Erytech Pharma SA, Esperance Pharmaceuticals Inc, Etubics Corp, Exelixis Inc, F. Hoffmann-La Roche Ltd, FibroGen Inc, Five Prime Therapeutics Inc, Fountain Biopharma Inc, Fujifilm Corp, Fusion Antibodies Ltd, Galena Biopharma Inc, GamaMabs Pharma SA, Ganymed Pharmaceuticals AG, Geistlich Pharma AG, Genelux Corp, Genentech Inc, Genisphere Inc, Genmab A/S, Gilead Sciences Inc, GlaxoSmithKline Plc, Globeimmune Inc, GlycoMimetics Inc, Golden Biotechnology Corp, GW Pharmaceuticals Plc, Halozyme Therapeutics Inc, HEC Pharm Co Ltd, Helix BioPharma Corp, Horizon Pharma Plc, iCeutica Inc, Igenica Biotherapeutics Inc, Ignyta Inc, Immodulon Therapeutics Ltd, Immune Pharmaceuticals Inc, Immune System Key Ltd, Immune Therapeutics Inc, Immunomedics Inc, Immunotope Inc, Immunovo BV, Immupharma Plc, Incuron LLC, Incyte Corp, Inflection Biosciences Ltd, Innopharmax Inc, Inovio Pharmaceuticals Inc, InteRNA Technologies BV, Intica Biomedical Inc, Inventiva, InvivoGen Therapeutics, Io Therapeutics Inc, ISU ABXIS Co Ltd, Jasco Pharmaceuticals LLC, Jiangsu Hengrui Medicine Co Ltd, Johnson & Johnson, Juno Therapeutics Inc, Kadmon Corp LLC, Kancera AB, Karcinolys SAS, Karyopharm Therapeutics Inc, Keystone Nano Inc, Komipharm International Co Ltd, Kura Oncology Inc, Kyowa Hakko Kirin Co Ltd, Lead Discovery Center GmbH, Lion Biotechnologies Inc, Lymphocyte Activation Technologies SA, MabVax Therapeutics Holdings Inc, MacroGenics Inc, Mateon Therapeutics Inc, MaxiVAX SA, Meabco A/S, Mebiopharm Co Ltd, MediaPharma srl, Medicenna Therapeutics Inc, MedImmune LLC, Medisyn Technologies Inc, Medivation Inc, Merck & Co Inc, Merck KGaA, Merrimack Pharmaceuticals Inc, Merus NV, Moleculin Biotech Inc, MolMed SpA, Monopar Therapeutics LLC, Morphotek Inc, Multimmune GmbH, NanoCarrier Co Ltd, NantKwest Inc, Nascent Biotech Inc, Natco Pharma Ltd, NatureWise Biotech & Medicals Corp, Nerviano Medical Sciences Srl, NewLink Genetics Corp, NormOxys Inc, Northwest Biotherapeutics Inc, Novartis AG, Noxxon Pharma AG, NuCana BioMed Ltd, Omeros Corp, Omnitura Therapeutics Inc, Oncodesign SA, Oncology Research International Ltd, Oncolytics Biotech Inc, Oncomatryx Biopharma SL, OncoMed Pharmaceuticals Inc, OncoTherapy Science Inc, Oncovir Inc, Ono Pharmaceutical Co Ltd, Onxeo SA, Opsona Therapeutics Ltd, Optimum Therapeutics LLC, Orega Biotech SAS, Oribase Pharma, Oryx GmbH & Co KG, Oscotec Inc, Patrys Ltd, Pfizer Inc, Pharma Two B Ltd, PharmAbcine Inc, Pharmacyclics Inc, PharmaCyte Biotech Inc, Pharmedartis GmbH, Phoenix Biotechnology Inc, Pique Therapeutics, Plexxikon Inc, Polaris Pharmaceuticals Inc, Precision Biologics Inc, Prima BioMed Ltd, ProNAi Therapeutics Inc, Propanc Health Group Corp, Provectus Biopharmaceuticals Inc, Quest PharmaTech Inc, Quimatryx SL, RedHill Biopharma Ltd, Redx Pharma Plc, RESprotect GmbH, Rexahn Pharmaceuticals Inc, Rhizen Pharmaceuticals SA, Rigontec GmbH, Samumed LLC, Sanofi, Sapience Therapeutics Inc, Sareum Holdings Plc, SATT North SAS, Savoy Pharmaceuticals Inc, SignPath Pharma Inc, Silence Therapeutics Plc, Sillajen Biotherapeutics, Soluventis GmbH, Soricimed Biopharma Inc, Spotlight Innovation Inc

About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at or call us at 1.800.844.8156.

Browse all Drug Pipeline research reports at Fast Market Research

You may also be interested in these related reports:

-Metastatic Pancreatic Cancer - Pipeline Review, H2 2016
-Metastatic Pancreatic Cancer - Pipeline Review, H2 2016
-Kidney Cancer (Renal Cell Cancer) - Pipeline Review, H2 2016
-Head And Neck Cancer - Pipeline Review, H2 2016
-Gastric Cancer - Pipeline Review, H2 2016